Therapy News and Research

RSS

Argon Medical to launch Cleaner15 technology for mechanical thrombectomy procedures

Furthering its commitment to advancing the treatment of patients diagnosed with ESRD (End Stage Renal Disease), Argon Medical Devices, Inc. takes another leap forward with the launch of the Cleaner15 Rotational Thrombectomy System.

17 Jan 2013

People with chronic inflammatory conditions may benefit from mindfulness meditation

People suffering from chronic inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and asthma - in which psychological stress plays a major role - may benefit from mindfulness meditation techniques, according to a study by University of Wisconsin-Madison neuroscientists with the Center for Investigating Healthy Minds at the Waisman Center.

17 Jan 2013

Some children with autism lose symptoms and diagnosis as they grow older

Some children who are accurately diagnosed in early childhood with autism lose the symptoms and the diagnosis as they grow older, a study supported by the National Institutes of Health has confirmed. The research team made the finding by carefully documenting a prior diagnosis of autism in a small group of school-age children and young adults with no current symptoms of the disorder.

16 Jan 2013

Study: Patients with EGFR exon 20 insertions need targeted therapies

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

16 Jan 2013

Speech training holds promise for cochlear implant recipients

Behavioral speech therapy programs are effective and efficient for training speech sound production in adults who have received a cochlear implant, exploratory research findings show.

16 Jan 2013

Researchers identify new group of growth factor receptors that signal to brain tumours

One in 25,000 people worldwide is affected by neurofibromatosis type 2 (NF2), a condition where the loss of a tumour suppressor called Merlin results in multiple tumours in the brain and nervous system.

16 Jan 2013

Stem cell transplantation prevents decrease in heart function associated with DMD

Researchers have shown that transplanting stem cells derived from normal mouse blood vessels into the hearts of mice that model the pathology associated with Duchenne muscular dystrophy (DMD) prevents the decrease in heart function associated with DMD.

16 Jan 2013

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.

16 Jan 2013

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

Cytos Biotechnology Ltd today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma.

16 Jan 2013

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Breast cancer is the second leading cause of cancer deaths among women in the United States. Many of these deaths occur when there is an initial diagnosis of invasive or metastatic disease. A protein called NEDD9-which regulates cell migration, division and survival-has been linked to tumor invasion and metastasis in a variety of cancers.

16 Jan 2013

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

16 Jan 2013

Patients with Parkinson's develop artistic talents after dopamine-inducing therapy

Parkinson's experts across the world have been reporting a remarkable phenomenon - many patients treated with drugs to increase the activity of dopamine in the brain as a therapy for motor symptoms such as tremors and muscle rigidity are developing new creative talents, including painting, sculpting, writing, and more.

16 Jan 2013

SLU researchers examine health outcomes for obese transplant recipients

In a research review article published in the American Journal of Nephrology, Saint Louis University investigators examined data from multiple studies to better understand how obesity, an epidemic in the U.S., impacts kidney transplant patients.

16 Jan 2013

p53 activation suppresses malic enzyme expression and leads to senescence in pre-cancerous cells

It is perhaps impossible to overstate the importance of the tumor suppressor gene p53. It is the single most frequently mutated gene in human tumors. p53 keeps pre-cancerous cells in check by causing cells, among other things, to become senescent - aging at the cellular level. Loss of p53 causes cells to ignore the cellular signals that would normally make mutant or damaged cells die or stop growing.

16 Jan 2013

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Increased NEK2 gene expression linked to increased drug resistance, faster cancer growth, and poorer patient outcome - The finding may improved diagnostic and prognostic tools for cancer care and could lead to improved cancer therapies

16 Jan 2013

Researchers discover molecular blueprint behind the IFIT protein

Researchers at McGill University and the Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences have discovered the molecular blueprint behind the IFIT protein.

15 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013

Therapy News and Research

Argon Medical to launch Cleaner15 technology for mechanical thrombectomy procedures

People with chronic inflammatory conditions may benefit from mindfulness meditation

Some children with autism lose symptoms and diagnosis as they grow older

Study: Patients with EGFR exon 20 insertions need targeted therapies

Speech training holds promise for cochlear implant recipients

Researchers identify new group of growth factor receptors that signal to brain tumours

Stem cell transplantation prevents decrease in heart function associated with DMD

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Patients with Parkinson's develop artistic talents after dopamine-inducing therapy

SLU researchers examine health outcomes for obese transplant recipients

p53 activation suppresses malic enzyme expression and leads to senescence in pre-cancerous cells

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Researchers discover molecular blueprint behind the IFIT protein

Aggressive breast cancer’s metastasis molecular switch identified

Tailored asthma therapy on the horizon

Dizziness does not hamper neck pain therapy

NSAID–antihypertensive combinations may risk kidney damage

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News